

# TABLE OF CONTENTS

Contributors . . . . .	xv
Preface . . . . .	xxvii
Acknowledgments . . . . .	xxviii

<b>1</b> Historical Principles and Perspectives . . . . .	1
<i>Paul M. Wax</i>	
<b>2</b> Toxicologic Plagues and Disasters in History . . . . .	18
<i>Paul M. Wax</i>	

## PART A

### THE GENERAL APPROACH TO MEDICAL TOXICOLOGY . . . . . 31

<b>3</b> Initial Evaluation of the Patient: Vital Signs and Toxic Syndromes . . . . .	33
<i>Lewis S. Nelson, Neal A. Lewin, Mary Ann Howland, Robert S. Hoffman, Lewis R. Goldfrank, and Neal E. Flomenbaum</i>	
<b>4</b> Principles of Managing the Acutely Poisoned or Overdosed Patient . . . . .	37
<i>Lewis S. Nelson, Neal A. Lewin, Mary Ann Howland, Robert S. Hoffman, Lewis R. Goldfrank, and Neal E. Flomenbaum</i>	
<b>5</b> Diagnostic Imaging . . . . .	45
<i>David T. Schwartz</i>	
<b>6</b> Laboratory Principles . . . . .	70
<i>Petrie M. Rainey</i>	
<b>7</b> Techniques Used to Prevent Gastrointestinal Absorption . . . . .	90
<i>Anne-Bolette Gude and Lotte C. G. Hoegberg</i>	
<b>A1</b> Syrup of Ipecac . . . . .	104
<i>Mary Ann Howland</i>	
<b>A2</b> Activated Charcoal . . . . .	108
<i>Mary Ann Howland</i>	
<b>A3</b> Whole-Bowel Irrigation and Other Intestinal Evacuants . . . . .	114
<i>Mary Ann Howland</i>	
<b>8</b> Pharmacokinetic and Toxicokinetic Principles . . . . .	119
<i>Mary Ann Howland</i>	
<b>9</b> Principles and Techniques Applied to Enhance Elimination . . . . .	135
<i>David S. Goldfarb</i>	
<b>10</b> Use of The Intensive Care Unit . . . . .	148
<i>Mark A. Kirk</i>	

## PART B

### THE FUNDAMENTAL PRINCIPLES OF MEDICAL TOXICOLOGY . . . . . 155

#### SECTION 1

Biochemical and Molecular Basis . . . . .	157
<b>11</b> Chemical Principles . . . . .	157
<i>Stephen J. Traub and Lewis S. Nelson</i>	
<b>12</b> Biochemical and Metabolic Principles . . . . .	170
<i>Kurt C. Kleinschmidt and Kathleen A. Delaney</i>	
<b>13</b> Neurotransmitters and Neuromodulators . . . . .	189
<i>Steven C. Curry, Kirk Charles Mills, Anne-Michelle Ruha, and Ayrn D. O'Connor</i>	
<b>14</b> Withdrawal Principles . . . . .	221
<i>Richard J. Hamilton</i>	

#### SECTION 2

Pathophysiologic Basis: Organ Systems . . . . .	228
<b>15</b> Thermoregulatory Principles . . . . .	228
<i>Susi U. Vassallo and Kathleen A. Delaney</i>	
<b>16</b> Fluid, Electrolyte, and Acid–Base Principles . . . . .	249
<i>Alan N. Charney and Robert S. Hoffman</i>	
<b>17</b> Psychiatric Principles . . . . .	265
<i>Kishor Malavade and Mark R. Serper</i>	
<b>18</b> Neurologic Principles . . . . .	275
<i>Rama B. Rao</i>	
<b>19</b> Ophthalmic Principles . . . . .	285
<i>Adhi Sharma</i>	
<b>20</b> Otolaryngologic Principles . . . . .	292
<i>William K. Chiang</i>	
<b>21</b> Respiratory Principles . . . . .	303
<i>Andrew Stolbach and Robert S. Hoffman</i>	
<b>22</b> Electrophysiologic and Electrocardiographic Principles . . . . .	314
<i>Cathleen Clancy</i>	
<b>23</b> Hemodynamic Principles . . . . .	330
<i>Robert A. Hessler</i>	
<b>24</b> Hematologic Principles . . . . .	340
<i>Marco L. A. Sivilotti</i>	

**25** Gastrointestinal Principles ..... 359  
*Richard G. Church and Kavita M. Babu*

**26** Hepatic Principles..... 367  
*Kathleen A. Delaney*

**27** Renal Principles ..... 381  
*Donald A. Feinfeld and Nikolas B. Harbord*

**28** Genitourinary Principles..... 396  
*Jason Chu*

**29** Dermatologic Principles ..... 410  
*Neal A. Lewin and Lewis S. Nelson*

**SECTION 3**

Special Populations ..... 423

**30** Reproductive and Perinatal Principles ..... 423  
*Jeffrey S. Fine*

**31** Pediatric Principles..... 447  
*Jeffrey S. Fine*

**32** Geriatric Principles..... 461  
*Judith C. Ahronheim and Mary Ann Howland*

**33** Postmortem Toxicology ..... 471  
*Rama B. Rao and Mark A. Flomenbaum*

**SCI** Organ Procurement from Poisoned Patients .... 479  
*Rama B. Rao*

**PART C**

THE CLINICAL BASIS OF MEDICAL TOXICOLOGY..... 481

**SECTION 1**

A. Analgesics and Antiinflammatory Medications... 483

**34** Acetaminophen..... 483  
*Robert G. Hendrickson*

**A4** N-Acetylcysteine..... 500  
*Mary Ann Howland and Robert G. Hendrickson*

**35** Salicylates..... 508  
*Neal E. Flomenbaum*

**A5** Sodium Bicarbonate..... 520  
*Paul M. Wax*

**36** Nonsteroidal Antiinflammatory Drugs..... 528  
*William J. Holubek*

**37** Colchicine, Podophyllin, and the Vinca Alkaloids... 537  
*Joshua G. Schier*

**SC2** Intrathecal Administration of Xenobiotics..... 548  
*Rama B. Rao*

**38** Opioids..... 559  
*Lewis S. Nelson and Dean Olsen*

**A6** Opioid Antagonists ..... 579  
*Mary Ann Howland and Lewis S. Nelson*

B. Foods, Dietary and Nutritional Xenobiotics..... 586

**39** Dieting Agents and Regimens ..... 586  
*Jeanna M. Marraffa*

**40** Iron..... 596  
*Jeanmarie Perrone*

**A7** Deferoxamine ..... 604  
*Mary Ann Howland*

**41** Vitamins..... 609  
*Beth Y. Ginsburg*

**42** Essential Oils..... 624  
*Sarah Eliza Halcomb*

**43** Herbal Preparations ..... 631  
*Oliver L. Hung*

**44** Athletic Performance Enhancers..... 654  
*Susi U. Vassallo*

**45** Food Poisoning..... 668  
*Michael G. Tunik*

**46** Botulism..... 682  
*Howard L. Geyer*

**A8** Botulinum Antitoxin ..... 695  
*Lewis R. Goldfrank and Howard L. Geyer*

C. Pharmaceuticals ..... 698

**47** Anticonvulsants ..... 698  
*Suzanne Doyon*

**A9** L-Carnitine..... 711  
*Mary Ann Howland*

**48** Antidiabetics and Hypoglycemics ..... 714  
*George M. Bosse*

**A10** Dextrose..... 728  
*Larissa I. Velez and Kathleen A. Delaney*

**A11** Octreotide ..... 734  
*Mary Ann Howland*

<b>49</b> Thyroid and Antithyroid Medications . . . . .	738	<b>A18</b> Insulin-Euglycemia Therapy . . . . .	893
<i>Nicole C. Bouchard</i>		<i>William Kerns</i>	
<b>50</b> Antihistamines and Decongestants . . . . .	748	<b>61</b> $\beta$ -Adrenergic Antagonists . . . . .	896
<i>Anthony J. Tomassoni and Richard S. Weisman</i>		<i>Jeffrey R. Brubacher</i>	
<b>A12</b> Physostigmine Salicylate . . . . .	759	<b>A19</b> Glucagon . . . . .	910
<i>Mary Ann Howland</i>		<i>Mary Ann Howland</i>	
<b>51</b> Antimigraine Medications . . . . .	763	<b>62</b> Other Antihypertensives . . . . .	914
<i>Jason Chu</i>		<i>Francis Jerome DeRoos</i>	
<b>52</b> Antineoplastics Overview . . . . .	770	<b>63</b> Antidysrhythmics . . . . .	925
<i>Richard Y. Wang</i>		<i>Lewis S. Nelson and Neal A. Lewin</i>	
<b>53</b> Antineoplastics: Methotrexate . . . . .	778	<b>64</b> Cardioactive Steroids . . . . .	936
<i>Richard Y. Wang</i>		<i>Jason B. Hack</i>	
<b>A13</b> Leucovorin (Folinic Acid) and Folic Acid . . . . .	783	<b>A20</b> Digoxin-Specific Antibody Fragments . . . . .	946
<i>Mary Ann Howland</i>		<i>Mary Ann Howland</i>	
<b>A14</b> Glucarpidase (Carboxypeptidase G <sub>2</sub> ) . . . . .	787	<b>65</b> Methylxanthines and Selective $\beta_2$ Adrenergic Agonists . . . . .	952
<i>Silas W. Smith</i>		<i>Robert J. Hoffman</i>	
<b>SC3</b> Extravasation of Xenobiotics . . . . .	793	F. Anesthetics and Related Medications . . . . .	965
<i>Richard Y. Wang</i>		<b>66</b> Local Anesthetics . . . . .	965
<b>54</b> Miscellaneous Antineoplastics . . . . .	796	<i>David R. Schwartz and Brian Kaufman</i>	
<i>Richard Y. Wang</i>		<b>A21</b> Intravenous Fat Emulsions . . . . .	976
<b>55</b> Pharmaceutical Additives . . . . .	803	<i>Theodore C. Bania</i>	
<i>Sean P. Nordt and Lisa E. Vivero</i>		<b>67</b> Inhalational Anesthetics . . . . .	982
D. Antimicrobials . . . . .	817	<i>Brian Kaufman and Martin Griffel</i>	
<b>56</b> Antibacterials, Antifungals, and Antivirals . . . . .	817	<b>68</b> Neuromuscular Blockers . . . . .	989
<i>Christine M. Stork</i>		<i>Kenneth M. Sutin</i>	
<b>57</b> Antituberculous Medications . . . . .	834	<b>A22</b> Dantrolene Sodium . . . . .	1001
<i>Christina H. Hernon and Edward W. Boyer</i>		<i>Kenneth M. Sutin</i>	
<b>A15</b> Pyridoxine . . . . .	845	G. Psychotropic Medications . . . . .	1003
<i>Mary Ann Howland</i>		<b>69</b> Antipsychotics . . . . .	1003
<b>58</b> Antimalarials . . . . .	849	<i>David N. Juurlink</i>	
<i>J. Dave Barry</i>		<b>70</b> Lithium . . . . .	1016
E. Cardiopulmonary Medications . . . . .	861	<i>Howard A. Greller</i>	
<b>59</b> Anticoagulants . . . . .	861	<b>71</b> Monoamine Oxidase Inhibitors . . . . .	1027
<i>Mark Su</i>		<i>Alex F. Manini</i>	
<b>A16</b> Vitamin K <sub>1</sub> . . . . .	876	<b>72</b> Serotonin Reuptake Inhibitors and Atypical Antidepressants . . . . .	1037
<i>Mary Ann Howland</i>		<i>Christine M. Stork</i>	
<b>A17</b> Protamine . . . . .	880	<b>73</b> Cyclic Antidepressants . . . . .	1049
<i>Mary Ann Howland</i>		<i>Erica L. Liebelt</i>	
<b>60</b> Calcium Channel Blockers . . . . .	884		
<i>Francis Jerome DeRoos</i>			

<b>74</b> Sedative-Hypnotics . . . . .	1060	<i>David C. Lee and Kathy Lynn Ferguson</i>
<b>A23</b> Flumazenil . . . . .	1072	<i>Mary Ann Howland</i>
H. Substances of Abuse . . . . .	1078	
<b>75</b> Amphetamines . . . . .	1078	<i>William K. Chiang</i>
<b>76</b> Cocaine . . . . .	1091	<i>Jane M. Prosser and Robert S. Hoffman</i>
<b>SC4</b> Internal Concealment of Xenobiotics . . . . .	1103	<i>Jane M. Prosser</i>
<b>A24</b> Benzodiazepines . . . . .	1109	<i>Robert S. Hoffman, Lewis S. Nelson, and Mary Ann Howland</i>
<b>77</b> Ethanol . . . . .	1115	<i>Luke Yip</i>
<b>A25</b> Thiamine Hydrochloride . . . . .	1129	<i>Robert S. Hoffman</i>
<b>78</b> Ethanol Withdrawal . . . . .	1134	<i>Jeffrey A. Gold and Lewis S. Nelson</i>
<b>79</b> Disulfiram and Disulfiram-Like Reactions . . . . .	1143	<i>Edwin K. Kuffner</i>
<b>80</b> $\gamma$ -Hydroxybutyric Acid . . . . .	1151	<i>Brenna M. Farmer</i>
<b>81</b> Inhalants . . . . .	1157	<i>Heather Long</i>
<b>82</b> Hallucinogens . . . . .	1166	<i>Kavita M. Babu</i>
<b>83</b> Cannabinoids . . . . .	1177	<i>Michael A. McGuigan</i>
<b>84</b> Nicotine . . . . .	1185	<i>Sari Soghoian</i>
<b>85</b> Phencyclidine and Ketamine . . . . .	1191	<i>Ruben E. Olmedo</i>
<b>86</b> Aluminum . . . . .	1202	<i>Brenna M. Farmer</i>
I. Metals . . . . .	1207	
<b>87</b> Antimony . . . . .	1207	<i>Asim F. Tarabar</i>
<b>88</b> Arsenic . . . . .	1214	<i>Stephen W. Munday and Marsha D. Ford</i>
<b>A26</b> Dimercaprol (British Anti-Lewisite or BAL) . . . . .	1229	<i>Mary Ann Howland</i>
<b>89</b> Bismuth . . . . .	1233	<i>Rama B. Rao</i>
<b>90</b> Cadmium . . . . .	1237	<i>Stephen J. Traub and Robert S. Hoffman</i>
<b>91</b> Chromium . . . . .	1243	<i>Steven B. Bird</i>
<b>92</b> Cobalt . . . . .	1248	<i>Gar Ming Chan, MD</i>
<b>93</b> Copper . . . . .	1256	<i>Lewis S. Nelson</i>
<b>94</b> Lead . . . . .	1266	<i>Fred M. Henretig</i>
<b>A27</b> Succimer (2,3-Dimercaptosuccinic Acid) . . . . .	1284	<i>Mary Ann Howland</i>
<b>A28</b> Edetate Calcium Disodium (CaNa <sub>2</sub> EDTA) . . . . .	1290	<i>Mary Ann Howland</i>
<b>95</b> Manganese . . . . .	1294	<i>Sari Soghoian</i>
<b>96</b> Mercury . . . . .	1299	<i>Young-Jin Sue</i>
<b>97</b> Nickel . . . . .	1308	<i>John A. Curtis and David A. Haggerty</i>
<b>98</b> Selenium . . . . .	1316	<i>Diane P. Calello</i>
<b>99</b> Silver . . . . .	1321	<i>Melisa W. Lai Becker and Michele Burns Ewald</i>
<b>100</b> Thallium . . . . .	1326	<i>Maria Mercurio-Zappala and Robert S. Hoffman</i>
<b>A29</b> Prussian Blue . . . . .	1334	<i>Robert S. Hoffman</i>
<b>101</b> Zinc . . . . .	1339	<i>Nima Majlesi</i>
J. Household Products . . . . .	1345	
<b>102</b> Antiseptics, Disinfectants, and Sterilants . . . . .	1345	<i>Paul M. Wax</i>
<b>103</b> Camphor and Moth Repellents . . . . .	1358	<i>Edwin K. Kuffner</i>
<b>104</b> Caustics . . . . .	1364	<i>Jessica A. Fulton</i>

- 105** Hydrofluoric Acid and Fluorides . . . . . 1374  
*Mark Su*
- A30** Calcium . . . . . 1381  
*Mary Ann Howland*
- 106** Hydrocarbons . . . . . 1386  
*David D. Gummin*
- 107** Toxic Alcohols . . . . . 1400  
*Sage W. Wiener*
- SC5** Diethylene Glycol . . . . . 1411  
*Joshua G. Schier*
- A31** Fomepizole . . . . . 1414  
*Mary Ann Howland*
- A32** Ethanol . . . . . 1419  
*Mary Ann Howland*
- K. Pesticides . . . . . 1423
- 108** Pesticides: An Overview of Rodenticides  
and a Focus on Principles . . . . . 1423  
*Neal E. Flomenbaum*
- 109** Barium . . . . . 1434  
*Andrew Dawson*
- 110** Sodium Monofluoroacetate and  
Fluoroacetamide . . . . . 1437  
*Fermin Barrueto, Jr.*
- 111** Phosphorus . . . . . 1440  
*Michael C. Beuhler*
- 112** Strychnine . . . . . 1445  
*Yiu-cheung Chan*
- 113** Insecticides: Organic Phosphorus  
Compounds and Carbamates . . . . . 1450  
*Michael Eddleston and Richard Franklin Clark*
- A33** Pralidoxime . . . . . 1467  
*Mary Ann Howland*
- A34** Atropine . . . . . 1473  
*Mary Ann Howland*
- 114** Insecticides: Organic Chlorines,  
Pyrethrins/Pyrethroids, and Insect Repellents . . . 1477  
*Michael G. Holland*
- 115** Herbicides . . . . . 1494  
*Darren M. Roberts*
- 116** Methyl Bromide and Other Fumigants . . . . . 1516  
*Keith K. Burkhart*
- L. Natural Toxins and Envenomations . . . . . 1522
- 117** Mushrooms . . . . . 1522  
*Lewis R. Goldfrank*
- 118** Plants . . . . . 1537  
*Mary Emery Palmer and Joseph M. Betz*
- 119** Arthropods . . . . . 1561  
*In-Hei Hahn*
- A35** Antivenom (Scorpion and Spider) . . . . . 1582  
*Richard Franklin Clark*
- 120** Marine Envenomations . . . . . 1587  
*D. Eric Brush*
- 121** Snakes and Other Reptiles . . . . . 1601  
*Bradley D. Riley, Anthony F. Pizon, and  
Anne-Michelle Ruha*
- A36** Antivenom (Crotaline) . . . . . 1611  
*Anthony F. Pizon, Bradley D. Riley, and  
Anne-Michelle Ruha*
- M. Occupational and Environmental Toxins . . . . . 1615
- 122** Industrial Poisoning: Information and  
Control . . . . . 1615  
*Peter H. Wald*
- 123** Nanotoxicology . . . . . 1625  
*Silas W. Smith*
- 124** Simple Asphyxiants and Pulmonary Irritants . . . 1643  
*Lewis S. Nelson and Oladapo A. Odujebi*
- 125** Carbon Monoxide . . . . . 1658  
*Christian Tomaszewski*
- A37** Hyperbaric Oxygen . . . . . 1671  
*Stephen R. Thom*
- 126** Cyanide and Hydrogen Sulfide . . . . . 1678  
*Christopher P. Holstege, Gary E. Isom,  
and Mark A. Kirk*
- A38** Sodium and Amyl Nitrite . . . . . 1689  
*Mary Ann Howland*
- A39** Sodium Thiosulfate . . . . . 1692  
*Mary Ann Howland*
- A40** Hydroxocobalamin . . . . . 1695  
*Mary Ann Howland*
- 127** Methemoglobin Inducers . . . . . 1698  
*Dennis P. Price*

<b>A41</b>	Methylene Blue . . . . .	1708
	<i>Mary Ann Howland</i>	
<b>128</b>	Smoke Inhalation . . . . .	1711
	<i>Nathan Phillip Charlton and Mark A. Kirk</i>	
	N. Disaster Preparedness . . . . .	1721
<b>129</b>	Risk Assessment and Risk Communication . . . . .	1721
	<i>Charles A. McKay</i>	
<b>130</b>	Hazmat Incident Response . . . . .	1727
	<i>Bradley J. Kaufman</i>	
<b>131</b>	Chemical Weapons . . . . .	1735
	<i>Jeffrey R. Suchard</i>	
<b>132</b>	Biological Weapons . . . . .	1750
	<i>Jeffrey R. Suchard</i>	
<b>133</b>	Radiation . . . . .	1759
	<i>Joseph G. Rella</i>	
<b>A42</b>	Potassium Iodide . . . . .	1775
	<i>Joseph G. Rella</i>	
<b>A43</b>	DTPA [Pentetic Acid or Pentetate (Zinc or Calcium) Trisodium] . . . . .	1779
	<i>Joseph G. Rella</i>	

## SECTION 2

Poison Centers and Epidemiology . . . . .	1782
<b>134</b> Poison Prevention and Education . . . . .	1782
	<i>Lauren Schwartz</i>
<b>135</b> Poison Centers and Poison Epidemiology . . . . .	1789
	<i>Robert S. Hoffman</i>
<b>136</b> International Perspectives on Medical Toxicology . . . . .	1796
	<i>Michael Eddleston</i>
<b>137</b> Principles of Epidemiology and Research Design . . . . .	1803
	<i>Kevin C. Osterhoudt</i>
<b>138</b> Adverse Drug Events and Postmarketing Surveillance . . . . .	1811
	<i>Louis R. Cantilena</i>
<b>139</b> Medication Safety and Adverse Drug Events . . . . .	1820
	<i>Brenna M. Farmer</i>
<b>140</b> Risk Management and Legal Principles . . . . .	1831
	<i>Barbara M. Kirrane and Dainius A. Drukteinis</i>
Index . . . . .	1839